Publications
1. Rinke, A.; Auernhammer, C.J.; Bodei, L.; Kidd, M.; Krug, S.; Lawlor, R.; Marinoni, I.; Perren, A.; Scarpa, A.; Sorbye, H., et al. Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalized medicine? . Gut 2021 accepted for publication / in press
2. Bechmann N, Moskopp ML, Ullrich M, Calsina B, Wallace PW, Richter S, Friedemann M, Langton K, Fliedner SMJ, Timmers HJLM, Nölting S, Beuschlein F, Fassnacht M, Prejbisz A, Pacak K, Ghayee HK, Bornstein SR, Dieterich P, Pietzsch J, Wielockx B, Robledo M, Qin N, Eisenhofer G. HIF2α supports pro-metastatic behavior in pheochromocytomas/paragangliomas. Endocr Relat Cancer. 2020 Nov;27(11):625-640. doi: 10.1530/ERC-20-0205. PMID: 33112842.
3. Eisenhofer G, Deutschbein T, Constantinescu G, Langton K, Pamporaki C, Calsina B, Monteagudo M, Peitzsch M, Fliedner S, Timmers HJLM, Bechmann N, Fankhauser M, Nölting S, Beuschlein F, Stell A, Fassnacht M, Prejbisz A, Lenders JWM, Robledo M. Plasma metanephrines and prospective prediction of tumor location, size and mutation type in patients with pheochromocytoma and paraganglioma. Clin Chem Lab Med. 2020 Oct 1;59(2):353-363. doi: 10.1515/cclm-2020-0904. PMID: 33001846.
4. Jiang J, Zhang J, Pang Y, Bechmann N, Li M, Monteagudo M, Calsina B, Gimenez- Roqueplo AP, Nölting S, Beuschlein F, Fassnacht M, Deutschbein T, Timmers HJLM, Åkerström T, Crona J, Quinkler M, Fliedner SMJ, Liu Y, Guo J, Li X, Guo W, Hou Y, Wang C, Zhang L, Xiao Q, Liu L, Gao X, Burnichon N, Robledo M, Eisenhofer G. Sino-European Differences in the Genetic Landscape and Clinical Presentation of Pheochromocytoma and Paraganglioma. J Clin Endocrinol Metab. 2020 Oct 1;105(10):dgaa502. doi: 10.1210/clinem/dgaa502. PMID: 32750708.
5. Jin XF, Spoettl G, Maurer J, Nölting S, Auernhammer CJ. Inhibition of Wnt/β-Catenin Signaling in Neuroendocrine Tumors in vitro: Antitumoral Effects. Cancers (Basel). 2020 Feb 4;12(2):345. doi: 10.3390/cancers12020345. PMID: 32033025; PMCID: PMC7072467.
6. Erlic Z, Kurlbaum M, Deutschbein T, Nölting S, Prejbisz A, Timmers H, Richter S, Prehn C, Weismann D, Adamski J, Januszewicz A, Reincke M, Fassnacht M, Robledo M, Eisenhofer G, Beuschlein F, Kroiss M. Metabolic impact of pheochromocytoma/paraganglioma: targeted metabolomics in patients before and after tumor removal. Eur J Endocrinol. 2019 Dec;181(6):647-657. doi:10.1530/EJE-19-0589. PMID: 31614337.
7. Nölting S, Ullrich M, Pietzsch J, Ziegler CG, Eisenhofer G, Grossman A, Pacak K. Current Management of Pheochromocytoma/Paraganglioma: A Guide for the Practicing Clinician in the Era of Precision Medicine. Cancers (Basel). 2019 Oct 8;11(10):1505. doi: 10.3390/cancers11101505. PMID: 31597347; PMCID: PMC6827093.
8. Siebert C, Ciato D, Murakami M, Frei-Stuber L, Perez-Rivas LG, Monteserin- Garcia JL, Nölting S, Maurer J, Feuchtinger A, Walch AK, Haak HR, Bertherat J, Mannelli M, Fassnacht M, Korpershoek E, Reincke M, Stalla GK, Hantel C, Beuschlein F. Heat Shock Protein 90 as a Prognostic Marker and Therapeutic Target for Adrenocortical Carcinoma. Front Endocrinol (Lausanne). 2019 Jul 19;10:487. doi: 10.3389/fendo.2019.00487. PMID: 31379752; PMCID: PMC6658895.
9. Fankhauser M, Bechmann N, Lauseker M, Goncalves J, Favier J, Klink B, William D, Gieldon L, Maurer J, Spöttl G, Rank P, Knösel T, Orth M, Ziegler CG, Aristizabal Prada ET, Rubinstein G, Fassnacht M, Spitzweg C, Grossman AB, Pacak K, Beuschlein F, Bornstein SR, Eisenhofer G, Auernhammer CJ, Reincke M, Nölting S. Synergistic Highly Potent Targeted Drug Combinations in Different Pheochromocytoma Models Including Human Tumor Cultures. Endocrinology. 2019 Nov 1;160(11):2600-2617. doi: 10.1210/en.2019-00410. PMID: 31322702; PMCID: PMC6795182.
10. Gieldon L, William D, Hackmann K, Jahn W, Jahn A, Wagner J, Rump A, Bechmann N, Nölting S, Knösel T, Gudziol V, Constantinescu G, Masjkur J, Beuschlein F, Timmers HJ, Canu L, Pacak K, Robledo M, Aust D, Schröck E, Eisenhofer G, Richter S, Klink B. Optimizing Genetic Workup in Pheochromocytoma and Paraganglioma by Integrating Diagnostic and Research Approaches. Cancers (Basel). 2019 Jun 11;11(6):809. doi: 10.3390/cancers11060809. PMID: 31212687; PMCID: PMC6627084.
11. Jin XF, Auernhammer CJ, Ilhan H, Lindner S, Nölting S, Maurer J, Spöttl G, Orth M. Combination of 5-Fluorouracil with Epigenetic Modifiers Induces Radiosensitization, Somatostatin Receptor 2 Expression, and Radioligand Binding in Neuroendocrine Tumor Cells In Vitro. J Nucl Med. 2019 Sep;60(9):1240-1246. doi: 10.2967/jnumed.118.224048. Epub 2019 Feb 22. PMID: 30796167.
12. Auernhammer CJ, Spitzweg C, Böck S, Knösel T, Bartenstein P. [Current standards and novel developments in the treatment of neuroendocrine tumors of the gastroenteropancreatic system]. Dtsch Med Wochenschr. 2019 Oct;144(20):1390-1395. doi: 10.1055/a-0801-3686. Epub 2019 Oct 8.PMID: 31594011 German.
13. Nölting S, Grossman A, Pacak K. Metastatic Phaeochromocytoma: Spinning Towards More Promising Treatment Options. Exp Clin Endocrinol Diabetes. 2019 Feb;127(2-03):117-128. doi: 10.1055/a-0715-1888. Epub 2018 Sep 20. PMID: 30235495; PMCID: PMC7443617.
14. Aristizabal Prada ET, Spöttl G, Maurer J, Lauseker M, Koziolek EJ, Schrader J, Grossman A, Pacak K, Beuschlein F, Auernhammer CJ, Nölting S. The role of GSK3 and its reversal with GSK3 antagonism in everolimus resistance. Endocr Relat Cancer. 2018 Oct;25(10):893-908. doi: 10.1530/ERC-18-0159. Epub 2018 Jun 12. PMID: 29895527; PMCID: PMC7439002.
15. Aristizabal Prada ET, Heinzle V, Knösel T, Nölting S, Spöttl G, Maurer J, Spitzweg C, Angele M, Schmidt N, Beuschlein F, Stalla GK, Blaser R, Kuhn KA, Auernhammer CJ. Tropomyosin receptor kinase: a novel target in screened neuroendocrine tumors. Endocr Relat Cancer. 2018 May;25(5):547-560. doi: 10.1530/ERC-17-0201. Epub 2018 Mar 21. PMID: 29563190.
16. Jin XF, Spampatti MP, Spitzweg C, Auernhammer CJ. Supportive therapy in gastroenteropancreatic neuroendocrine tumors: Often forgotten but important. Rev Endocr Metab Disord. 2018 Jun;19(2):145-158. doi: 10.1007/s11154-018-9443-6.PMID: 29464446 Review.
17. Auernhammer CJ, Spitzweg C, Angele MK, Boeck S, Grossman A, Nölting S, Ilhan H, Knösel T, Mayerle J, Reincke M, Bartenstein P. Advanced neuroendocrine tumours of the small intestine and pancreas: clinical developments, controversies, and future strategies. Lancet Diabetes Endocrinol. 2018 May;6(5):404-415. doi: 10.1016/S2213-8587(17)30401-1. Epub 2017 Dec 8. PMID: 29229497.
18. Aristizabal Prada ET, Auernhammer CJ. Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets.Endocr Connect. 2018 Jan;7(1):R1-R25. doi: 10.1530/EC-17-0286. Epub 2017 Nov 16.PMID: 29146887 Free PMC article. Review.
19. Aristizabal Prada ET, Weis C, Orth M, Lauseker M, Spöttl G, Maurer J, Grabowski P, Grossman A, Auernhammer CJ, Nölting S. GSK3α/β: A Novel Therapeutic Target for Neuroendocrine Tumors. Neuroendocrinology. 2018;106(4):335-351. doi: 10.1159/000481887. Epub 2017 Oct 2. PMID: 28968593.
20. Nölting S, Rentsch J, Freitag H, Detjen K, Briest F, Möbs M, Weissmann V, Siegmund B, Auernhammer CJ, Aristizabal Prada ET, Lauseker M, Grossman A, ExnerS, Fischer C, Grötzinger C, Schrader J, Grabowski P; GERMAN NET-Z study group. The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models. PLoS One. 2017 Aug 11;12(8):e0182852. doi: 10.1371/journal.pone.0182852. PMID: 28800359; PMCID: PMC5553670.
21. Aristizabal Prada ET, Orth M, Nölting S, Spöttl G, Maurer J, Auernhammer C. The MTH1 inhibitor TH588 demonstrates anti-tumoral effects alone and in combination with everolimus, 5-FU and gamma-irradiation in neuroendocrine tumor cells. PLoS One. 2017 May 25;12(5):e0178375. doi: 10.1371/journal.pone.0178375. PMID: 28542590; PMCID: PMC5444855.
22. Angelousi A, Dimitriadis GK, Zografos G, Nölting S, Kaltsas G, Grossman A. Molecular targeted therapies in adrenal, pituitary and parathyroid malignancies. Endocr Relat Cancer. 2017 Jun;24(6):R239-R259. doi: 10.1530/ERC-16-0542. Epub 2017 Apr 11. PMID: 28400402.
23. Aristizabal Prada ET, Nölting S, Spoettl G, Maurer J, Auernhammer CJ. The Novel Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) Alone and in Dual-Targeting Approaches Demonstrates Antitumoral Efficacy in Neuroendocrine Tumors in vitro. Neuroendocrinology. 2018;106(1):58-73. doi: 10.1159/000463386.Epub 2017 Feb 23. PMID: 28226315.
24. Reuther C, Heinzle V, Nölting S, Herterich S, Hahner S, Halilovic E, Jeay S, Wuerthner JU, Aristizabal Prada ET, Spöttl G, Maurer J, Auernhammer CJ. The HDM2 (MDM2) Inhibitor NVP-CGM097 Inhibits Tumor Cell Proliferation and Shows Additive Effects with 5-Fluorouracil on the p53-p21-Rb-E2F1 Cascade in the p53wild type Neuroendocrine Tumor Cell Line GOT1. Neuroendocrinology. 2018;106(1):1-19. doi: 10.1159/000453369. Epub 2016 Nov 21. PMID: 27871087.
25. Nölting S, Maurer J, Spöttl G, Aristizabal Prada ET, Reuther C, Young K, Korbonits M, Göke B, Grossman A, Auernhammer CJ. Additive Anti-Tumor Effects of Lovastatin and Everolimus In Vitro through Simultaneous Inhibition of Signaling Pathways. PLoS One. 2015 Dec 4;10(12):e0143830. doi: 10.1371/journal.pone.0143830. PMID: 26636335; PMCID: PMC4670204.
26. Reuther C, Heinzle V, Spampatti M, Vlotides G, de Toni E, Spöttl G, Maurer J, Nölting S, Göke B, Auernhammer CJ. Cabozantinib and Tivantinib, but Not INC280, Induce Antiproliferative and Antimigratory Effects in Human Neuroendocrine Tumor Cells in vitro: Evidence for 'Off-Target' Effects Not Mediated by c-Met Inhibition. Neuroendocrinology. 2016;103(3-4):383-401. doi: 10.1159/000439431. Epub 2015 Aug 25. PMID: 26338447.
27. Schovanek J, Bullova P, Tayem Y, Giubellino A, Wesley R, Lendvai N, Nölting S, Kopacek J, Frysak Z, Pommier Y, Kummar S, Pacak K. Inhibitory Effect of the Noncamptothecin Topoisomerase I Inhibitor LMP-400 on Female Mice Models and Human Pheochromocytoma Cells. Endocrinology. 2015 Nov;156(11):4094-104. doi: 10.1210/en.2015-1476. Epub 2015 Aug 12. PMID: 26267380; PMCID: PMC4606751.
28. Vlotides G, Tanyeri A, Spampatti M, Zitzmann K, Chourdakis M, Spttl C, Maurer J, Nölting S, Göke B, Auernhammer CJ. Anticancer effects of metformin on neuroendocrine tumor cells in vitro. Hormones (Athens). 2014 Oct- Dec;13(4):498-508. doi: 10.14310/horm.2002.1517. Epub 2014 Nov 5. PMID: 25402373.
29. Spampatti M, Vlotides G, Spöttl G, Maurer J, Göke B, Auernhammer CJ. Aspirin inhibits cell viability and mTOR downstream signaling in gastroenteropancreatic and bronchopulmonary neuroendocrine tumor cells. World J Gastroenterol. 2014 Aug 7;20(29):10038-49. doi: 10.3748/wjg.v20.i29.10038.PMID: 25110431 Free PMC article.
30. Fliedner SM, Engel T, Lendvai NK, Shankavaram U, Nölting S, Wesley R, Elkahloun AG, Ungefroren H, Oldoerp A, Lampert G, Lehnert H, Timmers H, Pacak K. Anti-cancer potential of MAPK pathway inhibition in paragangliomas-effect of different statins on mouse pheochromocytoma cells. PLoS One. 2014 May 20;9(5):e97712. doi: 10.1371/journal.pone.0097712. PMID: 24846270; PMCID: PMC4028222.
31. Nölting S, Giubellino A, Tayem Y, Young K, Lauseker M, Bullova P, Schovanek J, Anver M, Fliedner S, Korbonits M, Göke B, Vlotides G, Grossman A, Pacak K. Combination of 13-Cis retinoic acid and lovastatin: marked antitumor potential in vivo in a pheochromocytoma allograft model in female athymic nude mice. Endocrinology. 2014 Jul;155(7):2377-90. doi: 10.1210/en.2014-1027. Epub 2014 Apr 24. PMID: 24762141; PMCID: PMC4060189.
32. Giubellino A, Bullova P, Nölting S, Turkova H, Powers JF, Liu Q, Guichard S, Tischler AS, Grossman AB, Pacak K. Combined inhibition of mTORC1 and mTORC2 signaling pathways is a promising therapeutic option in inhibiting pheochromocytoma tumor growth: in vitro and in vivo studies in female athymic nude mice. Endocrinology. 2013 Feb;154(2):646-55. doi: 10.1210/en.2012-1854. Epub 2013 Jan 10. PMID: 23307788; PMCID: PMC3548182.
33. Zitzmann K, Ailer G, Vlotides G, Spoettl G, Maurer J, Göke B, Beuschlein F, Auernhammer CJ. Potent antitumor activity of the novel HSP90 inhibitors AUY922 and HSP990 in neuroendocrine carcinoid cells. Int J Oncol. 2013 Dec;43(6):1824-32. doi: 10.3892/ijo.2013.2130. Epub 2013 Oct 4.PMID: 24100469 Free PMC article.
34. Zitzmann K, Andersen S, Vlotides G, Spöttl G, Zhang S, Datta R, Culler M, Göke B, Auernhammer CJ. The novel somatostatin receptor 2/dopamine type 2 receptor chimeric compound BIM-23A758 decreases the viability of human GOT1 midgut carcinoid cells. Neuroendocrinology. 2013;98(2):128-36. doi: 10.1159/000353784. Epub 2013 Jul 31.PMID: 23797089
35. Nölting S, Garcia E, Alusi G, Giubellino A, Pacak K, Korbonits M, Grossman AB. Combined blockade of signalling pathways shows marked anti-tumour potential in phaeochromocytoma cell lines. J Mol Endocrinol. 2012 Jul 25;49(2):79-96. Doi: 10.1530/JME-12-0028. PMID: 22715163; PMCID: PMC4714579.
36. Nölting S, Grossman AB. Signaling pathways in pheochromocytomas and paragangliomas: prospects for future therapies. Endocr Pathol. 2012 Mar;23(1):21-33. doi: 10.1007/s12022-012-9199-6. PMID: 22391976.
37. Zitzmann K, Vlotides G, Brand S, Lahm H, Spöttl G, Göke B, Auernhammer CJ. Perifosine-mediated Akt inhibition in neuroendocrine tumor cells: role of specific Akt isoforms. Endocr Relat Cancer. 2012 May 24;19(3):423-34. doi: 10.1530/ERC-12-0074. Print 2012 Jun.PMID: 22499437
38. Nölting S, Kuttner A, Lauseker M, Vogeser M, Haug A, Herrmann KA, Hoffmann JN, Spitzweg C, Göke B, Auernhammer CJ. Chromogranin a as serum marker for gastroenteropancreatic neuroendocrine tumors: a single center experience and literature review. Cancers (Basel). 2012 Feb 15;4(1):141-55. doi: 10.3390/cancers4010141. PMID: 24213232; PMCID: PMC3712684.
39. Zitzmann K, de Toni E, von Rüden J, Brand S, Göke B, Laubender RP, Auernhammer CJ. The novel Raf inhibitor Raf265 decreases Bcl-2 levels and confers TRAIL-sensitivity to neuroendocrine tumour cells. Endocr Relat Cancer. 2011 Mar 21;18(2):277-85. doi: 10.1530/ERC-10-0108. Print 2011 Apr.PMID: 21317202
40. Auernhammer CJ, Göke B. Therapeutic strategies for advanced neuroendocrine carcinomas of jejunum/ileum and pancreatic origin.Gut. 2011 Jul;60(7):1009-21. doi: 10.1136/gut.2009.204453. Epub 2011 Mar 4.PMID: 21378384 Review.
41. Zitzmann K, Rüden Jv, Brand S, Göke B, Lichtl J, Spöttl G, Auernhammer CJ. Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease. Cancer Lett. 2010 Sep 1;295(1):100-9. doi: 10.1016/j.canlet.2010.02.018. Epub 2010 Mar 30.PMID: 20356670
42. Zitzmann K, Vlotides G, Göke B, Auernhammer CJ. PI(3)K-Akt-mTOR pathway as a potential therapeutic target in neuroendocrinetumors. Expert Rev Endocrinol Metab. 2008 Mar;3(2):207-222. doi: 10.1586/17446651.3.2.207.PMID: 30764093
43. Zitzmann K, Brand S, De Toni EN, Baehs S, Göke B, Meinecke J, Spöttl G, Meyer HH, Auernhammer CJ. SOCS1 silencing enhances antitumor activity of type I IFNs by regulating apoptosis in neuroendocrine tumor cells. Cancer Res. 2007 May 15;67(10):5025-32. doi: 10.1158/0008-5472.CAN-06-2575.PMID: 17510435
44. Zitzmann K, De Toni EN, Brand S, Göke B, Meinecke J, Spöttl G, Meyer HH, Auernhammer CJ. The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. Neuroendocrinology. 2007;85(1):54-60. doi: 10.1159/000100057. Epub 2007 Feb 19.PMID: 17310129